Navigation Links
Harris Corporation Teams with Cancer Treatment Services International to Advance Oncology Treatment
Date:2/25/2008

Harris Expands Enterprise Intelligence Systems to Healthcare Market

ORLANDO, Fla., Feb. 25 /PRNewswire-FirstCall/ -- HIMSS, Booth #1841 -- Harris Corporation (NYSE: HRS), an international communications and information technology company, has joined forces with Cancer Treatment Services International (CTSI) to advance the quality and delivery of radiation oncology. Harris will provide advanced imaging and information systems that assure critical medical information is delivered with accuracy, speed, security and privacy.

"We believe Harris' expertise in image processing and enterprise intelligence will significantly advance radiation oncology," said Dr. Jeff Shogan, MD and chairman of CTSI. "Our collaboration with Harris will enhance our ability to deliver the highest quality cancer treatment services to more people, more effectively."

"We are very pleased to be working with CTSI and Dr. Shogan, who is a leading practitioner and innovator in cancer treatment services on an international scale," said Jim Traficant, vice president of Harris Healthcare Solutions. "We have been working closely with Dr. Shogan to leverage our imaging and informatics expertise to deliver enterprise intelligence to radiation oncology."

CTSI L.P. is a provider of comprehensive treatment for cancer patients with a main focus on medical oncology and radiation oncology. The company was founded by a core group of physicians and businessmen with substantial experience in the development, operation and networking of cancer services on a national and international level. CTSI is able to provide innovative and technologically-advanced treatment solutions to areas of the world where therapy is currently inadequate in either quality or capacity.
'/>"/>

SOURCE Harris Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Harris Methodist Fort Worth Hospital Using Bubbles to Help Babies Breathe
2. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
3. CEL-SCI Corporation Releases Letter to Shareholders
4. Alfacell Corporation to Present at UBS Global Life Sciences Conference
5. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
6. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
7. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
8. The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
9. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
10. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
11. Immunosyn Corporation Releases SF-1019 Study Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Mass. , Jan. 15, 2014  Zafgen, Inc., ... unmet needs of severely obese patients, today announced ... beloranib, a selective inhibitor of methionine aminopeptidase 2 ... severe form of genetic obesity.  These results showed ...
(Date:1/14/2014)...  Luminex Corporation (Nasdaq: LMNX ) today announced that ... 2013 on Monday, February 3, 2014. A press release announcing ... trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... highlights and financial results for the fourth quarter and twelve ...
(Date:1/14/2014)... Dynamic Healthcare Services, Inc. ("DHS"), a portfolio company of GMH ... Medical Equipment, Inc. ("Progressive") of Clarion, PA ... were not disclosed. Progressive is a full ... of sleep, mobility, and respiratory products to customers in the ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... Solutions LLC today announced the launch of their ... a minimally invasive, Board Certified, OB/GYN surgeon Dr. ... improve patient and surgical team safety.  This proprietary device ... and reload sutures with an efficient, one-handed motion resulting ...
... (Nasdaq: BMRN ) announced today that the ... study (PKU-016) to evaluate the effects of Kuvan (sapropterin ...  BioMarin expects to report results in the first half ... will provide quantitative data regarding the neuropsychiatric effects of ...
Cached Medicine Technology:Equinox Surgical Solutions Launches Flagship Product, SutureAssist® 2BioMarin Initiates Phase 3b Study to Evaluate the Effects of Kuvan on Neurophychiatric Symptoms in Subjects with PKU 2BioMarin Initiates Phase 3b Study to Evaluate the Effects of Kuvan on Neurophychiatric Symptoms in Subjects with PKU 3
(Date:4/17/2014)... of the most popular vaccine brands for children may ... be overlooking some cost factors when choosing vaccines, driving ... option, according to a new study by University of ... can be driven by numerous factors," says Sheldon H. ... of computer science and of mathematics at the U. ...
(Date:4/17/2014)... 17, 2014) Two recent papers by a ... colleagues may help scientists develop treatments or vaccines ... Japanese encephalitis and other disease-causing flaviviruses. , Jeffrey ... molecular genetics at the School of Medicine and ... Medical Institute, and colleagues recently published articles in ...
(Date:4/17/2014)... April 17, 2014U.S. military personnel who served in ... concussive traumatic brain injury (TBI) were compared to ... other medical reasons. Differences in measures of overall ... months after injury are reported in an article ... journal from Mary Ann Liebert, Inc., publishers. The ...
(Date:4/17/2014)... about one in five infants in the United States ... first several months after birth. Research into probiotic use ... the April 1, 2014 issue of the British ... study, "Probiotics and Infant Colic," concluding that the use ... colic did not reduce crying or fussing in ...
(Date:4/17/2014)... Calif.) An international team led by researchers at ... complex, which plays a key role in cell division, ... This is the first time the complex has been ... make cyclin B1/Cdk1 an excellent target to control cellular ... The research was published online today in the journal ...
Breaking Medicine News(10 mins):Health News:Study recalculates costs of combination vaccines 2Health News:CU researchers discover target for treating dengue fever 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Dual role: Key cell division proteins also power up mitochondria 2
... (Providence, RI)--- EpiVax, Inc, a leader in the field ... funding from the Juvenile Diabetes Research Foundation (JDRF), the ... to develop Epi-13, a novel therapeutic for the prevention ... chronic autoimmune disease that affects up to three million ...
... 2007 - Diseases that cause neurons to break-down, ... (Mad Cow Disease), continue to be elusive to ... from University of Michigan researchers demonstrates an unpredicted ... neuron health., In a study released in PNAS, ...
... ElBaradei will join more than 100 leading public figures, ... in New York on 29 October to mark the ... the US based National Foundation for Cancer Research (NFCR). ... PACT Fund at NFCR, Americans can support the IAEA ...
... is generally considered to be safe with a low ... tube can lead to serious complications. , The ... Dr. Imamura of Aichi Medical University Hospital. It was ... Gastroenterology. , An 86-year-old woman with gastrostomy tube feeding ...
... ALTO, Calif., Oct. 25 ASTRO Booth # ... today announced that it has developed,groundbreaking technology for ... of volumetric arc therapy. Varian,s new RapidArc(TM),radiotherapy technology* ... to deliver more precise forms of intensity-modulated radiation,therapy ...
... Coley,Pharmaceutical Group, Inc. (Nasdaq: COLY ), today announced ... 4:30 p.m. Eastern Time on November,1, 2007 to discuss ... live audio broadcast or the subsequent archived recording,of the ... Coley website,at http://www.coleypharma.com . Please log onto Coley,s ...
Cached Medicine News:Health News:EpiVax receives JDRF program funding to develop diabetes drug using natural 'regulatory' T-cells 2Health News:U-M scientists find new causes for neurodegeneration 2Health News:IAEA and NFCR join forces to fight cancer in developing world 2Health News:Varian Medical Systems to Introduce RapidArc(TM) Radiotherapy Technology for Volumetric Arc Therapy at ASTRO 2007 2Health News:Varian Medical Systems to Introduce RapidArc(TM) Radiotherapy Technology for Volumetric Arc Therapy at ASTRO 2007 3Health News:Varian Medical Systems to Introduce RapidArc(TM) Radiotherapy Technology for Volumetric Arc Therapy at ASTRO 2007 4Health News:Coley Pharmaceutical Group to Report Third Quarter Results on November 1, 2007 2
Curved shafts with fine pointed tips. Smooth handle with dull finish....
Delicate curved shafts with light crisscross serrations. Serrated handle with polished finish. Most popular size or model....
Delicate cross serrated lightly curved tips with serrated handle and polished finish. Most popular size or model....
Delicate lightly curved tips, 1 x 2 mouse style teeth. Serrated handle with polished finish....
Medicine Products: